Search research articles
Contact Us
Filters
Showing results (131-140 of 167) with videos related to
Page
of 17
Sort By:
JAMA Network Open
|
January 5, 2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
Brandon M Huffman, Atrayee Basu Mallick, Nora K Horick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 9, 2013
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis
Dominic E Sanford, Brian A Belt, Roheena Z Panni, et al.
Journal of Cancer Therapy
|
October 4, 2013
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Dominic E Sanford, Matthew R Porembka, Roheena Z Panni, et al.
JAMA Oncology
|
December 16, 2016
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Vincent Chung, Shannon McDonough, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer
Patrick M Grierson, Crystal Wolf, Rama Suresh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2017
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, et al.
The Lancet. Diabetes & Endocrinology
|
May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Cancer Research
|
December 11, 2012
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses
Jonathan B Mitchem, Donal J Brennan, Brett L Knolhoff, et al.
Lancet (London, England)
|
November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 167) with videos related to
Sort By:
Page
of 17
JAMA Network Open
|
January 5, 2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
Brandon M Huffman, Atrayee Basu Mallick, Nora K Horick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 9, 2013
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis
Dominic E Sanford, Brian A Belt, Roheena Z Panni, et al.
Journal of Cancer Therapy
|
October 4, 2013
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Dominic E Sanford, Matthew R Porembka, Roheena Z Panni, et al.
JAMA Oncology
|
December 16, 2016
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Vincent Chung, Shannon McDonough, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer
Patrick M Grierson, Crystal Wolf, Rama Suresh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2017
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, et al.
The Lancet. Diabetes & Endocrinology
|
May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Cancer Research
|
December 11, 2012
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses
Jonathan B Mitchem, Donal J Brennan, Brett L Knolhoff, et al.
Lancet (London, England)
|
November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Page
of 17